Hydroxyure in pregnancy
I'll check the medical library skill first, then search for information on hydroxyurea in pregnancy.
Reading File
Now I'll search the medical library and PubMed in parallel for hydroxyurea in pregnancy.
Finding Sources
Searching PubMed
hydroxyurea pregnancy sickle cell
Good results. Let me now read the relevant textbook sections and get the abstract of the recent systematic review in parallel.
Reading File
Reading File
Reading Article
PMID: 40381805
I now have excellent information from multiple authoritative sources. Let me compile a comprehensive answer.
Hydroxyurea in Pregnancy
Overview
Hydroxyurea (HU) is an antimetabolite/ribonucleotide reductase inhibitor used in sickle cell disease (SCD), chronic myeloid leukemia (CML), essential thrombocythemia (ET), polycythemia vera (PV), and psoriasis. Its use in pregnancy is a nuanced topic that has evolved in recent years.
FDA Pregnancy Classification
Hydroxyurea is classified as FDA Category D (older classification) - meaning there is positive evidence of human fetal risk. It is listed as a known teratogen based on animal studies and limited human data, and has historically been contraindicated in pregnancy and lactation.
- Fitzpatrick's Dermatology, 9e - Absolute contraindications include active pregnancy/lactation.
- Dermatology 2-Volume Set 5e - Described as a "known teratogen; not to be used during pregnancy or lactation."
Mechanism of Concern
HU inhibits DNA synthesis by blocking ribonucleotide reductase. This affects rapidly dividing cells, which includes fetal tissue - raising concern for:
- Congenital malformations
- Intrauterine growth restriction
- Fetal hematologic suppression (myelosuppression)
- Teratogenicity (especially first trimester)
Indications Where the Question Arises
1. Sickle Cell Disease (Most Common Scenario)
HU is the cornerstone therapy for SCD, reducing vaso-occlusive crises by increasing fetal hemoglobin (HbF). Pregnant women with SCD face difficult choices:
- Traditional guidance: Discontinue HU at least 3 months before conception
- Harrison's 22e (2025): Addresses HU in the context of SCD pregnancy management
- The underlying disease (SCD) itself carries significant pregnancy risks: preterm birth, maternal death, preeclampsia, vaso-occlusive crises
2. Myeloproliferative Neoplasms (ET, PV)
- Goldman-Cecil Medicine: "Hydroxyurea should be avoided, including during the breast-feeding period." Interferon is the preferred cytoreductive agent in pregnancy for ET/PV when treatment is required, as it is generally considered safe.
Updated Evidence (2025 Systematic Review)
A major 2025 systematic review by Al Sulaimani et al. in J Obstet Gynaecol Can reviewed 7,227 pregnancies (567 HU-exposed):
| Finding | Detail |
|---|---|
| Studies included | 15 studies, published 1993-2023 |
| HU-exposed pregnancies | 567 (7.8%) |
| Primary diagnosis | SCD (n=502), CML (n=26), ET (n=24) |
| Teratogenic effects | None observed |
| Hematologic fetal effects | None observed |
| Conclusion | "Pregnancy risks associated with HU are lower than anticipated. Use may be justified given significant risks of untreated SCD." |
⚠️ Important caveat: Quality of evidence is low (observational data). Traditional guidance to discontinue HU ≥3 months before conception is still widely recommended pending more robust evidence.
Practical Clinical Guidance
| Situation | Recommendation |
|---|---|
| Planning pregnancy (SCD) | Discontinue HU ≥3 months before conception; counsel about risks |
| Inadvertent exposure in 1st trimester | Discontinue immediately; refer to high-risk obstetrics; discuss risks |
| SCD in pregnancy (uncontrolled) | Consider risk-benefit - new evidence suggests HU may be used when maternal risk without treatment is very high |
| ET/PV in pregnancy | Prefer interferon-alpha over HU for cytoreduction |
| Breastfeeding | Contraindicated - HU is excreted in breast milk |
| Male partners on HU | Use adequate contraception - HU can impair sperm motility and spermatogenesis |
Key Adverse Effects Profile (General)
- Myelosuppression (most common) - anemia, leukopenia, thrombocytopenia
- Megaloblastosis (occurs in all patients on HU)
- Dermatomyositis-like eruption
- Transient hepatitis / elevated liver enzymes
- Sporadic renal toxicity
- Fever / flu-like illness (rare)
- Increased risk of nonmelanoma skin cancer (long-term use)
Fitzpatrick's Dermatology recommends discontinuing HU if Hb drops by >3 g/dL, WBC <4,000/mm³, or platelets <100,000/mm³.
Pre-Pregnancy Counseling Checklist
Per Fitzpatrick's:
- Pregnancy test in all women of childbearing age before initiating HU
- Counsel on teratogenic risk and need for contraception
- Males should also use contraception
- Discuss the 3-month washout before attempting conception
Summary
Hydroxyurea is traditionally contraindicated in pregnancy (Category D, known teratogen in animals). However, the most recent 2025 systematic review (PMID: 40381805) of 567 HU-exposed pregnancies found no teratogenic or fetal hematologic effects, suggesting risks may be lower than historically assumed. The clinical decision must balance:
- Disease severity (especially SCD, where untreated disease carries serious maternal/fetal risk)
- Gestational timing of exposure
- Availability of safer alternatives (interferon-alpha for myeloproliferative neoplasms)
For SCD in pregnancy, a multidisciplinary team including hematology and high-risk obstetrics should guide management. For myeloproliferative neoplasms, interferon-alpha remains the preferred cytoreductive agent during pregnancy.
This is a shared conversation. Sign in to Orris to start your own chat.